Hologic Inc.
Hologic Approves New PSU Award Agreements for Fiscal 2025
Summary
On November 5, 2024, Hologic, Inc.'s Compensation Committee approved revised Performance Stock Unit (PSU) Award Agreements for fiscal 2025. These agreements provide for vesting based on achieving specific financial goals such as return on invested capital (ROIC), three-year relative total shareholder return (relative TSR), and free cash flow (FCF). The new agreements are detailed in Exhibits 10.1, 10.2, and 10.3, which are incorporated by reference into this report.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement